Eisai and Bial’s epilepsy drug Zebinix has shown effectiveness on par with that of the current standard of care in newly diagnosed focal epilepsy patients. Eisai and Bial’s epilepsy drug Zebinix has ...

HATFIELD, England, February 10, 2011 /PRNewswire/ -- Zebinix(R) (eslicarbazepine acetate), an add-on (adjunctive) therapy for adults with partial-onset seizures, with or without secondary ...

HATFIELD, England, April 19, 2011 /PRNewswire/ -- Zebinix(R) (eslicarbazepine acetate), an add-on (adjunctive) therapy for adults with partial-onset seizures, with or without secondary generalisation ...

Patients with epilepsy in the UK will from this week have access to a novel treatment after Eisai launched Zebinix, a follow-on drug from the current gold standard therapy carbamazepine. atients with ...

Wayne, PA, USA, Porto, Portugal. July 15, 2014 – BIAL a research based international pharmaceutical company and moksha8 a leading specialty pharmaceutical company in Latin America announced today an ...

PORTO AND LJUBLJANA, 19 July 2021 – BIAL and Medis, d.o.o. announce that they have entered into an exclusive partnership on two BIAL's proprietary drugs: Zebinix ® (eslicarbazepine acetate) and ...

Positive data from three phase III studies presented today at theAmerican Epilepsy Society (AES) Congress, Seattle, USA, show thatZebinix(TM)(1) (eslicarbazepine acetate), a novel once-daily ...

- Novel Treatment Also Demonstrated Significant Improvement in Quality ofLife and Reduction in Depressive Symptoms Zebinix(TM) is one of the proposed EU trade names for eslicarbazepineacetate. In ...

PORTO, Portugal, 18 February – BIAL announces the end of the licence agreement established in 2009. BIAL takes the lead for the marketing and distribution of Zebinix ® (eslicarbazepine acetate) in ...

Kingdom, Denmark, Norway, Iceland, Sweden, Portugal* Albania*, Cyprus*, Malta* and Spain (co promotion with BIAL from launch). *Exclusively by BIAL Notes to Editors Zebinix(R) is the EU trade name for ...

improvement in seizure control with existing anti-epileptic drugs.